Lauren Grygotis, Editor

The FDA has granted Fast Track designation for GLPG1972/S201086 for the treatment of patients with osteoarthritis.

Experts at the 2018 ACR/ARHP Annual Meeting discuss whether hydroxychloroquine dosing should be more than 5 mg/kg in patients with systemic lupus erythematosus.

Upadacitinib resulted in greater improvements in rheumatoid arthritis signs and symptoms compared with placebo and adalimumab.

When the analysis was limited to studies that examined bDMARDs vs no-treatment placebo controls, bDMARDs had a substantial benefit on physical health, measured by the Physical Component Summary, compared with mental health.